Trident Lifeline Ltd
Incorporated in 2014, Trident Lifeline Ltd manufactures and sells pharmaceuticals
products[1]
- Market Cap ₹ 336 Cr.
- Current Price ₹ 292
- High / Low ₹ 339 / 144
- Stock P/E 32.0
- Book Value ₹ 56.1
- Dividend Yield 0.00 %
- ROCE 18.0 %
- ROE 17.9 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Earnings include an other income of Rs.8.23 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| 22 | 32 | 45 | 87 | |
| 19 | 25 | 36 | 72 | |
| Operating Profit | 3 | 6 | 8 | 15 |
| OPM % | 12% | 20% | 18% | 17% |
| 1 | 1 | 2 | 8 | |
| Interest | 0 | 0 | 1 | 4 |
| Depreciation | 0 | 0 | 1 | 5 |
| Profit before tax | 3 | 7 | 9 | 14 |
| Tax % | -32% | 8% | 32% | 23% |
| 4 | 6 | 6 | 10 | |
| EPS in Rs | 4.94 | 5.24 | 5.51 | 10.22 |
| Dividend Payout % | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 59% |
| TTM: | 95% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 39% |
| TTM: | 77% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 63% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 17% |
| Last Year: | 18% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Equity Capital | 8 | 12 | 12 | 12 |
| Reserves | -3 | 34 | 41 | 53 |
| 2 | 8 | 18 | 54 | |
| 7 | 9 | 16 | 38 | |
| Total Liabilities | 14 | 63 | 87 | 156 |
| 1 | 3 | 21 | 44 | |
| CWIP | 0 | 5 | 4 | 2 |
| Investments | 0 | 3 | 4 | 11 |
| 12 | 51 | 58 | 100 | |
| Total Assets | 14 | 63 | 87 | 156 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| -0 | -19 | 2 | -10 | |
| -0 | -10 | -20 | -14 | |
| 1 | 42 | 11 | 20 | |
| Net Cash Flow | 0 | 14 | -7 | -4 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Debtor Days | 83 | 139 | 110 | 116 |
| Inventory Days | 95 | 129 | 156 | 226 |
| Days Payable | 134 | 87 | 94 | 118 |
| Cash Conversion Cycle | 44 | 182 | 173 | 224 |
| Working Capital Days | 67 | 319 | 251 | 236 |
| ROCE % | 23% | 15% | 18% |
Documents
Announcements
-
Announcement Under Regulation 30- Cessation Of Corporate Office
1d - Corporate office ceases at Surat location; books moved to registered office from 22 May 2025.
-
Intimation Under Regulation 30 Of SEBI (LODR) Regulations, 2015 -Launch Of New Skin Care Brand 'YES' By Subsidiary Company- TLL Elements Private Limited
12 May - Subsidiary TLL Elements launched new domestic skincare brand 'YES' on May 12, 2025.
- Scrutinizer"S Report 12 May
-
Shareholder Meeting / Postal Ballot-Outcome of EGM
9 May - EOGM held to approve capital increase and preferential issuance of convertible equity warrants.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
30 Apr - Trident Lifeline Limited hereby enclose copies of newspaper advertisement published on April 30, 2025 regarding extract of the Audited Standalone and Consolidated Financial Statements for …
Business Overview:[1]
TFL is a pharmaceutical Company with business operations spanning formulations under its own brands, loan licence model and contract manufacturing model.
a) Pharmaceutical formulations export:
Company has a presence in 40 countries, including African, Latin America, and East
Asian countries, with ~945 registered export market products, and ~2016 export market products are under registration
b) Contract manufacturing:
Company follows an Asset-light third-party contract manufacturing model thus entailing limited direct investment in manufacturing capacities